OMEGA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 2021 between Omega Therapeutics, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
Omega Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Omega Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
LEASE by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company and OMEGA THERAPEUTICS, INC. a Delaware corporationLease • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS LEASE (this “Lease”) is entered into as of this 30th day of November, 2017 (the “Execution Date”), by and between BMR-325 Vassar Street LLC, a Delaware limited liability company (“Landlord”), and Omega Therapeutics, Inc., a Delaware corporation (“Tenant”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 24, 2021, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Roger Sawhney, M.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Development and Option Agreement by and between ACUITAS THERAPEUTICS, INC. and OMEGA THERAPEUTICS, INC. dated October 5, 2020Development and Option Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), dated as of October 5, 2020 (the “Effective Date”), is made by and between Omega Therapeutics, Inc. a Delaware corporation (“Omega”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Omega and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
SHARED SPACE ARRANGEMENTShared Space Arrangement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This shared space arrangement (this “Shared Space Arrangement”) is made and entered into as of the 13th day of July, 2020 (the “Effective Date”) by and between Kintai Therapeutics, Inc., a Delaware corporation (“Licensor”), and Omega Therapeutics, Inc., a Delaware corporation (“Licensee”), with an address as identified on the signature page of this Shared Space Arrangement (the “Signature Page”).
OMEGA THERAPEUTICS, INC. PACIFIC WESTERN BANK LOAN AND SECURITY AGREEMENTLoan and Security Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • North Carolina
This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of March 9, 2018, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and OMEGA THERAPEUTICS, INC. (“Borrower”).
